Program
quizartinib
Also written as “Quizartinib”, “AC220” and “Quizartinib High Dose”.
Its studies are mostly in Leukemia, Myeloid, Acute, led by 2 companies.
Drug pageQuizartinib: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyoits history only | 214 open or running | phase 3since Jan 15, 2014 | Apr 17, 2007 | May 1, 2027phase 2 · NCT03793478 |
| Kura Oncology | 11 open or running | phase 1since Feb 9, 2023 | Feb 9, 2023 | Apr 2030phase 1 · NCT05735184 |
Also a collaborator on its studies: Quotient Sciences and Ambit Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kura Oncology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 9, 2023First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT05735184 · 420 planned · United States
Ahead
- Apr 2030Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT05735184
TargetBeta
“Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor”ChEMBL 37, by rule
Studies
The one study Kura Oncology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05735184Leukemia, Myeloid, Acute · United States | 1 | Recruiting | Apr 2030 | 420 |
How it is read
Names in the registry
- “Quizartinib”, 15 entries
- “AC220”, 5 entries
- “Quizartinib High Dose”, 1 entry
- “Quizartinib Low Dose”, 1 entry
- “Quizartinib dihydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 15 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.